Overview

Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease

Status:
Completed
Trial end date:
2003-06-01
Target enrollment:
0
Participant gender:
All
Summary
There were 2 study periods in this study. In the Period 1, CP-690,550 was to be administered approximately 1 to 2 hours following hemodialysis. If significant non-renal clearance of the drug occurred such that dialyzability of CP-690,550 could not be assessed in Period 1, a second period (Period 2) will be conducted. In Period 2, a single dose of drug will be administered approximately 4 hours prior to hemodialysis.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Treatments:
Tofacitinib
Criteria
Inclusion Criteria:

- Subjects with end-stage renal disease

- Subjects need hemodialysis 3 times weekly

Exclusion Criteria:

- Subjects with evidence or history of clinically significant disease, excluding those
common for subjects with End-Stage Renal Disease (ESRD).

- Subjects with any condition possibly affecting drug absorption.

- Subjects with malignancies with the exception of adequately treated basal cell
carcinoma of the skin.